Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
about
Vaccines for gonorrhea: can we rise to the challenge?Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrheaCurrent and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challengeAntimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and futurePreparing for an era of untreatable gonorrheaThe use of cephalosporins for gonorrhea: an update on the rising problem of resistance.Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management.Antimicrobial stewardship - can we afford to do without it?Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009.Sublethal exposure to commercial formulations of the herbicides dicamba, 2,4-dichlorophenoxyacetic acid, and glyphosate cause changes in antibiotic susceptibility in Escherichia coli and Salmonella enterica serovar Typhimurium.High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failureFirst comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial speciesAntibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future.Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae in Korea.Current epidemiology and growing resistance of gram-negative pathogens.In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeaeManagement of gonococcal infection among adults and youth: New key recommendations.Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeaeAssessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy studyAntimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillanceA retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrheaNew Ceftriaxone- and Multidrug-Resistant Neisseria gonorrhoeae Strain with a Novel Mosaic penA Gene Isolated in Japan.Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century.Utility of specimens positive for Neisseria gonorrhoeae by the Aptima Combo 2 assay for assessment of strain diversity and antibiotic resistanceAssessment of Etest as an alternative to agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeaeIs gonorrhea becoming untreatable?Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials.Managing sexually transmitted infections in pregnant women.The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting.Current and future treatment options for gonorrhoea.Moving forward in tackling antimicrobial resistance: WHO actions.Gonococcal antimicrobial resistance: perspectives from the African region.Gonococcal antimicrobial resistance in the Western Pacific Region.New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.Persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea is influenced by antibiotic susceptibility and reinfection.Combination therapy for gonorrhoea: in vitro synergy testing.Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.Management of Gonorrhea in Adolescents and Adults in the United States.
P2860
Q21131153-24241AE9-8396-48A7-8B1F-65F4215EE5D0Q24633203-D09BA300-C728-4746-829E-6F17458F0A9DQ26796265-A4B8DD70-9874-424F-946F-6737BA999808Q26862597-55443AD5-6C42-4FDE-BD76-C6CF18F742B9Q27002771-2B153B96-D38E-4505-853A-FD09B0185134Q33836057-7E2E354F-857F-40C5-B096-DD0BC8B455CBQ34632863-10FFBF36-B029-45B0-A15D-3D8D8D837CA4Q35023684-BDCC7777-4036-4150-AA69-4B1E511267A9Q35065794-2EA09532-3E3F-47FA-97C6-EF0DB06383E7Q35139554-E0F579FF-EE18-432E-B151-F02D74ECC097Q35677458-78F0C8CD-39DD-4C3F-8DE2-45623D3F4AABQ35806206-AB9ED08A-C18C-4BBC-8F49-8A6BFD2FE02EQ35867842-78EE38B9-5636-4D10-B67A-B2C66790881BQ35878450-A574EE3B-B3F6-4ACF-AA21-BB9313B50091Q35962785-C3375C7E-365E-4252-9CFE-E7A909FED5DFQ36025192-D1176CCE-7B08-4A9F-8640-5797523C5BB1Q36086360-89E748AE-88F0-415F-A902-56683D80C22DQ36136318-AE1869DE-1311-425A-B923-185F626DB83CQ36166278-FEA96D08-5016-4313-A6EF-8340467175A2Q36360329-0A13E6A5-E97D-4646-ABB9-59E5E750DC84Q36462151-CD445ED7-A3D7-4C82-9F51-CAB5B381C289Q36723212-14F0D8CC-8429-448C-86F6-BDF4BB49F545Q36811237-68A717A2-FE16-41AD-BECE-016C17DC7ED0Q37023276-9626A3B1-DA19-40A9-A458-98D787201673Q37036002-06D49F3C-4C7C-4224-9780-673DD56F7CE8Q37336216-0E8840C8-CF93-4760-A5DF-D423C786D92EQ37713705-977B9455-D6F0-41C9-B543-86A5562AE276Q37844851-0F82542B-11B4-4478-B289-EC590550505CQ37994153-B6E56FA1-7D1F-4758-9FD3-544566615CBCQ38007203-BC085414-DF75-4F4E-92FB-A35FBCED4BC8Q38011099-0CE48133-9E67-471B-956D-4FA9F42AA356Q38150832-823A5930-BF8F-4510-A8B1-AEA1BC24EEB2Q38160730-39751ABB-582C-401F-99C5-170F9B49DBF1Q38163511-699FABD1-7B14-4A34-8E05-04EB7A583E06Q38163512-3C7B9156-BECE-4628-96FE-E7EFCDE64A3DQ38675370-BBD24A71-468B-48CE-AB75-EF60194CA56FQ39129305-CD4FA7F2-C4EF-4C97-A9C9-F95C2BD2027BQ39519913-81790149-BD48-4229-801D-3043D74DE531Q40053318-CE95D514-7DE2-410B-8583-9DE6D456CB73Q40279995-B5346518-5D76-43A3-8615-EAC12D4A08DA
P2860
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
@en
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
@nl
type
label
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
@en
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
@nl
prefLabel
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
@en
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
@nl
P2093
P2860
P356
P1476
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
@en
P2093
Catherine A Ison
David A Lewis
David M Livermore
Stephanie A Chisholm
Tom Nichols
P2860
P304
P356
10.1093/JAC/DKQ289
P407
P50
P577
2010-08-06T00:00:00Z